Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results

Entera Bio (NASDAQ:ENTXGet Rating) posted its quarterly earnings data on Thursday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05, Fidelity Earnings reports. Entera Bio had a negative net margin of 2,134.33% and a negative return on equity of 59.83%. During the same quarter in the previous year, the business posted ($0.43) EPS.

Entera Bio stock opened at $2.15 on Friday. The company’s fifty day simple moving average is $2.49 and its 200-day simple moving average is $2.78. Entera Bio has a 12 month low of $1.72 and a 12 month high of $8.68.

Several institutional investors have recently bought and sold shares of the company. Morgan Stanley grew its holdings in shares of Entera Bio by 145.6% during the 3rd quarter. Morgan Stanley now owns 5,378 shares of the company’s stock valued at $25,000 after acquiring an additional 3,188 shares in the last quarter. PNC Financial Services Group Inc. purchased a new position in shares of Entera Bio during the 1st quarter valued at $29,000. Jane Street Group LLC acquired a new stake in shares of Entera Bio in the 3rd quarter valued at $54,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Entera Bio in the 4th quarter valued at $113,000. Institutional investors and hedge funds own 23.87% of the company’s stock.

Separately, B. Riley lowered their price target on shares of Entera Bio from $11.00 to $6.00 in a report on Monday, January 24th.

Entera Bio Company Profile (Get Rating)

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures.

See Also

Earnings History for Entera Bio (NASDAQ:ENTX)

Receive News & Ratings for Entera Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entera Bio and related companies with MarketBeat.com's FREE daily email newsletter.